MENU
QGEN
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

QGEN stock forecast, quote, news & analysis

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
QGEN
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for QGEN with price predictions
Oct 22, 2026

Momentum Indicator for QGEN turns positive, indicating new upward trend

QGEN saw its Momentum Indicator move above the 0 level on October 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 51 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 56%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for QGEN just turned positive on October 05, 2026. Looking at past instances where QGEN's MACD turned positive, the stock continued to rise in 22 of 40 cases over the following month. The odds of a continued upward trend are 55%.

QGEN moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where QGEN advanced for three days, in 141 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 53%.

The Aroon Indicator entered an Uptrend today. In 108 of 193 cases where QGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

QGEN broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.075) is normal, around the industry mean (66.046). P/E Ratio (25.152) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (1.201) is also within normal values, averaging (3.473). QGEN's Dividend Yield (0.028) is considerably higher than the industry average of (0.002). P/S Ratio (4.255) is also within normal values, averaging (9.775).

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. QGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

A.I.Advisor
published Dividends

QGEN paid dividends on July 14, 2026

Qiagen NV QGEN Stock Dividends
А dividend of $0.35 per share was paid with a record date of July 14, 2026, and an ex-dividend date of July 07, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 21.22B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -3%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 43%. MYGN experienced the highest price growth at 32%, while MDXH experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 54%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 107%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 42
SMR Rating: 78
Profit Risk Rating: 89
Seasonality Score: 26 (-100 ... +100)
Momentum Indicator for QGEN turns positive, indicating new upward trend